Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4CNS 4Genitourinary 1

Conditions

Prostatic Neoplasms 7Urinary Bladder Neoplasms 4Carcinoma, Renal Cell 4Kidney Neoplasms 3Urethral Neoplasms 1Non-Metastatic Prostate Cancer 1Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter 1Locally Advanced Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Filgrastim 10Carboplatin 10Ifosfamide 9Paclitaxel 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7X-Rays 5Specimen Handling 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Thiotepa 4Nuclear Medicine Department, Hospital 4Melphalan 4Cisplatin 4Busulfan 4Biopsy 4pegfilgrastim 3etoposide phosphate 3Temozolomide 3Granulocyte Colony-Stimulating Factor 3tazemetostat 2olaparib 2larotrectinib 2ixabepilone 2erdafitinib 2ensartinib 2Vemurafenib 2Stem Cell Transplantation 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Gefitinib × Genitourinary × Clear all
NCT00085566 2016-01-20

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
61 enrolled 8 charts
CNSGenitourinarySarcoma

Brain Neoplasms, Glioblastoma, Prostatic Neoplasms, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡